BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med 2014;55:799-804. [PMID: 24627434 DOI: 10.2967/jnumed.113.132118] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Reference Citation Analysis]
2 Li D, Cheng S, Zou S, Zhu D, Zhu T, Wang P, Zhu X. Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody. Mol Pharm 2018;15:1674-81. [PMID: 29502426 DOI: 10.1021/acs.molpharmaceut.8b00062] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
3 Li YC, Yang CS, Zhou WL, Li HS, Han YJ, Wang QS, Wu HB. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. World J Gastroenterol 2018; 24(4): 494-503 [PMID: 29398870 DOI: 10.3748/wjg.v24.i4.494] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
4 Lu RC, She B, Gao WT, Ji YH, Xu DD, Wang QS, Wang SB. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 2019; 25(32): 4682-4695 [PMID: 31528094 DOI: 10.3748/wjg.v25.i32.4682] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
5 Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma. 2016;3:63-67. [PMID: 27878117 DOI: 10.2147/jhc.s116513] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
6 van de Watering FC, Rijpkema M, Perk L, Brinkmann U, Oyen WJ, Boerman OC. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int 2014;2014:203601. [PMID: 24991539 DOI: 10.1155/2014/203601] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
7 Wang Z, Han YJ, Huang S, Wang M, Zhou WL, Li HS, Wang QS, Wu HB. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids 2018;50:309-20. [PMID: 29204748 DOI: 10.1007/s00726-017-2517-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
8 Marquez BV, Zheleznyak A, Lapi SE. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma: Where antibody imaging dares to tread. J Nucl Med. 2014;55:708-709. [PMID: 24665087 DOI: 10.2967/jnumed.113.136234] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
9 An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, Huang G, Liu J. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging 2022. [PMID: 35147737 DOI: 10.1007/s00259-022-05723-x] [Reference Citation Analysis]
10 Labadie KP, Ludwig AD, Lehnert AL, Hamlin DK, Kenoyer AL, Sullivan KM, Daniel SK, Mihailovic TN, Sham JG, Orozco JJ, Yeung RS, Chen DL, Wilbur DS, Miyaoka RS, Park JO. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Sci Rep 2021;11:3731. [PMID: 33580090 DOI: 10.1038/s41598-021-82172-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li W, Xiao X, Li X, Xu Y, Ma L, Guo L, Yan C, Wu Y. Detecting GPC3-Expressing Hepatocellular Carcinoma with L5 Peptide-Guided Pretargeting Approach: In Vitro and In Vivo MR Imaging Experiments. Contrast Media Mol Imaging 2018;2018:9169072. [PMID: 30275801 DOI: 10.1155/2018/9169072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
12 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang Q, Zhang P, Li Z, Feng X, Lv C, Zhang H, Xiao H, Ding J, Chen X. Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. Theranostics 2019;9:1426-52. [PMID: 30867842 DOI: 10.7150/thno.31683] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
14 Wang K, Kievit FM, Sham JG, Jeon M, Stephen ZR, Bakthavatsalam A, Park JO, Zhang M. Iron-Oxide-Based Nanovector for Tumor Targeted siRNA Delivery in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. Small 2016;12:477-87. [PMID: 26641029 DOI: 10.1002/smll.201501985] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
15 Chen R, Bai Y, Liu T, Zhang G, Han Y, Chen L, Gao H, Wei W, Wang M. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging. Acad Radiol 2021;28:e227-34. [PMID: 32540197 DOI: 10.1016/j.acra.2020.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yan J, Yu X, Chen X, Liu F, Chen F, Ding N, Yu L, Meng F, Shen J, Wei J, Liu B. Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma. Front Oncol 2021;11:679336. [PMID: 34150644 DOI: 10.3389/fonc.2021.679336] [Reference Citation Analysis]
17 Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 28.5] [Reference Citation Analysis]
18 Chen Q, Chen AZ, Jia G, Li J, Zheng C, Chen K. Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34738743 DOI: 10.1002/hep4.1850] [Reference Citation Analysis]
19 Marquez BV, Ikotun OF, Zheleznyak A, Wright B, Hari-Raj A, Pierce RA, Lapi SE. Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts. Mol Pharm 2014;11:3988-95. [PMID: 25058168 DOI: 10.1021/mp500323d] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
20 Houvast RD, Vankemmelbeke M, Durrant LG, Wuhrer M, Baart VM, Kuppen PJK, de Geus-Oei LF, Vahrmeijer AL, Sier CFM. Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers (Basel) 2020;12:E3870. [PMID: 33371487 DOI: 10.3390/cancers12123870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Marquez BV, Lapi SE. Pretargeted Immuno-PET: Overcoming Limitations of Space and Time. J Nucl Med 2016;57:332-3. [DOI: 10.2967/jnumed.115.168096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
22 Tian Y, Liu Z, Zhang L, Zhang J, Han X, Wang Q, Cheng W. Apatinib-loaded lipid nanobubbles combined with ultrasound-targeted nanobubble destruction for synergistic treatment of HepG2 cells in vitro. Onco Targets Ther 2018;11:4785-95. [PMID: 30127626 DOI: 10.2147/OTT.S170786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Yu S, Li Z, Li J, Zhao S, Wu S, Liu H, Bi X, Li D, Dong J, Duan S, Hammock BD. Generation of Dual functional Nanobody-Nanoluciferase Fusion and its potential in Bioluminescence Enzyme Immunoassay for trace Glypican-3 in Serum. Sens Actuators B Chem 2021;336:129717. [PMID: 35250176 DOI: 10.1016/j.snb.2021.129717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
24 Natarajan A, Zhang H, Ye W, Huttad L, Tan M, Chua MS, Gambhir SS, So SK. A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. Cancers (Basel) 2021;13:3977. [PMID: 34439132 DOI: 10.3390/cancers13163977] [Reference Citation Analysis]
25 Filippi L, Schillaci O. New kid on the block in theranostics: Glypican-3. Clin Transl Imaging 2021;9:199-201. [DOI: 10.1007/s40336-021-00413-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741-767. [PMID: 28621802 DOI: 10.1002/med.21455] [Cited by in Crossref: 87] [Cited by in F6Publishing: 100] [Article Influence: 17.4] [Reference Citation Analysis]
27 Zhang Q, Han Z, Tao J, Zhao M, Zhang W, Li P, Tang L, Gu Y. An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Biomater Sci 2018;7:159-67. [PMID: 30417190 DOI: 10.1039/c8bm01016a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
28 Hoogenboom TC, Thursz M, Aboagye EO, Sharma R. Functional imaging of hepatocellular carcinoma. Hepat Oncol 2016;3:137-53. [PMID: 30191034 DOI: 10.2217/hep-2015-0005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Sham JG, Kievit FM, Grierson JR, Chiarelli PA, Miyaoka RS, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma. J Nucl Med. 2014;55:2032-2037. [PMID: 25359880 DOI: 10.2967/jnumed.114.145102] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
30 De Rose F, Braeuer M, Braesch-Andersen S, Otto AM, Steiger K, Reder S, Mall S, Nekolla S, Schwaiger M, Weber WA, Bartolazzi A, D'Alessandria C. Galectin-3 Targeting in Thyroid Orthotopic Tumors Opens New Ways to Characterize Thyroid Cancer. J Nucl Med 2019;60:770-6. [PMID: 30361380 DOI: 10.2967/jnumed.118.219105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
31 Qin Y, Cheng S, Li Y, Zou S, Chen M, Zhu D, Gao S, Wu H, Zhu L, Zhu X. The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma. Biomater Sci 2020;8:5656-65. [PMID: 32896851 DOI: 10.1039/d0bm00943a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, Wu H, Chen K. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Mol Imaging Biol 2020;22:134-43. [PMID: 31044341 DOI: 10.1007/s11307-019-01356-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
33 Zhu D, Qin Y, Wang J, Zhang L, Zou S, Zhu X, Zhu L. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. Bioconjugate Chem 2016;27:831-9. [DOI: 10.1021/acs.bioconjchem.6b00030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
34 Feng GK, Ye JC, Zhang WG, Mei Y, Zhou C, Xiao YT, Li XL, Fan W, Wang F, Zeng MS. Integrin α6 targeted positron emission tomography imaging of hepatocellular carcinoma in mouse models. J Control Release 2019;310:11-21. [PMID: 31400382 DOI: 10.1016/j.jconrel.2019.08.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
35 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
36 Campbell DO, Noda A, Verlinsky A, Snyder J, Fujita Y, Murakami Y, Fushiki H, Miyoshi S, Lacayo S, Cabral E, Yang P, Stover DR, Joseph IBJ.. Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys. Mol Imaging Biol 2016;18:768-75. [DOI: 10.1007/s11307-016-0953-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Lam K, Chan C, Reilly RM. Development and preclinical studies of 64Cu-NOTA-pertuzumab F(ab')2 for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT. MAbs 2017;9:154-64. [PMID: 27813707 DOI: 10.1080/19420862.2016.1255389] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
38 Yao G, Yin J, Wang Q, Dong R, Lu J. Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells. Biomed Res Int 2019;2019:2560650. [PMID: 31781603 DOI: 10.1155/2019/2560650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
39 Ludwig AD, Labadie KP, Seo YD, Hamlin DK, Nguyen HM, Mahadev VM, Yeung RS, Wilbur DS, Park JO. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma. J Oncol 2019;2019:4564707. [PMID: 31636665 DOI: 10.1155/2019/4564707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]